Karyopharm Therapeutics Inc. (KPTI)
After hours:
| Previous close | 1.1350 |
| Open | 1.1500 |
| Bid | 1.1400 x 800 |
| Ask | 1.1700 x 800 |
| Day's range | 1.1250 - 1.1900 |
| 52-week range | 0.6170 - 2.6700 |
| Volume | |
| Avg. volume | 1,312,871 |
| Market cap | 135.366M |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2024 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 15 at 9:30 a.m. ET.
- PR Newswire
Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2024, and highlighted select corporate milestones and progress on its key clinical development programs.
- PR Newswire
Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced today that it has entered into a series of financing transactions that will extend the Company's debt maturities into 2028 and 2029, well beyond the Company's planned Phase 3 data readouts in 2025.
